cancer drug

News
Roche Rituxan approval

Roche’s Perjeta combo approved in Europe for early breast ca...

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.